MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage multiple intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Most important trial objectives had been to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exp... https://sarolaner66432.livebloggs.com/37101650/z-lehd-fmk-options